RUNA digital repository

    • Español
    • Galego
    • English
  • English 
    • Español
    • Galego
    • English
  • Login
RUNABibliosaúdeXunta de galicia. Consellería de sanidadeServicio Galego de saúde
  • REPOSITORY
  • ABOUT US
    • About RUNA
    • Normative
    • Sergas Policy
  • HELP
    • Help
    • FAQ
  •   RUNA Home
  • Scientific publication
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Treatment of lysosomal storage diseases: recent patents and future strategies

Ortolano, S.; Vieitez, I.; Navarro, C.; Spuch, C.
Thumbnail
Statistics
Statistics
View Usage Statistics
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/5752
PMID: 24433521
DOI: 10.2174/1872214808666140115111350
ISSN: 1872-2148
Full record
Services
Services
RISMendeleyLinksolver
Date issued
2014
Journal title
Recent patents on endocrine, metabolic & immune drug discovery.
Type of content
Artigo
MeSH
Cell- and Tissue-Based Therapy | Drug Delivery Systems | Enzyme Inhibitors | Enzyme Replacement Therapy | Genetic Therapy | Humans | Lysosomal Storage Diseases | Models, Biological | Molecular Chaperones | Patents as Topic
Abstract
Lysosomal storage diseases (LSDs) are a group of rare genetic multisystemic disorders, resulting in deficient lysosomal activity. These pathologies are characterized by progressive accumulation of storage material within the lysosomes, ultimately leading to organ dysfunctions. LSDs patient's clinical outcomes have significantly improved, since the advent of enzyme replacement therapy (ERT). ERT is approved worldwide for 6 LSDs: Gaucher disease, Fabry disease, Mucopolysaccharidosis types I, II, and VI, and Pompe disease. The efficacy and safety of ERT for LSDs has been confirmed by extensive clinical trials, however therapy with infused protein is life-long and disease progression is still observed in treated patients. Obstacles to successful ERT, such as immune reactions against the infused enzyme, miss-targeting of recombinant enzymes, and difficult delivery to crucial tissues (i.e. brain and bone), determine the need for further research, in order to ameliorate therapeutic strategies. Viral gene therapy, stem cell based therapy, pharmacological chaperones and could be considered essential tools for future improvement of recombinant enzyme trafficking and targeting. This review will discuss recent patents and new strategic approaches for enzyme delivery to highlight the most relevant aspects, concerning next generation LSDs treatment.

Browse

All of RUNACollectionsCentersAuthorsTitlesDeCSMeSHCIETypes of contentThis CollectionCentersAuthorsTitlesDeCSMeSHCIETypes of content

Statistics

View Usage Statistics

OF INTEREST

About Open AccessCopyright
TwitterRSS
Xunta de Galicia
© Xunta de Galicia. Información mantida e publicada na internet pola Consellería de Sanidade o Servizo Galego de Saúde
Legal warning | RSS
Galicia